Completed PHASE2 INTERVENTIONAL NCT00201318

A Randomized Study in Non-Hodgkin's Lymphoma Patients Carrying Hepatitis B Surface Antigen

A Randomized Study of Lamivudine Prophylaxis or Treatment Against Hepatitis B Reactivation in Non-Hodgkin's Lymphoma Patients Carrying Hepatitis B Surface Antigen

Sponsor: Chi Mei Medical Hospital

Conditions Non-Hodgkin's Lymphoma

Interventions Cyclophosphamide Doxorubicin Vincristine Lamivudine

Updated 5 times since 2017 Last updated: Sep 13, 2005 Started: Sep 30, 2001 Completion: Oct 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Non-Hodgkin's Lymphoma and is currently completed. Chi Mei Medical Hospital leads this study, which shows 5 recorded versions since 2001 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Sep 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chi Mei Medical Hospital
Mackay Memorial Hospital
National Cheng-Kung University Hospital
National Health Research Institutes, Taiwan
National Taiwan University Hospital
Taipei Veterans General Hospital, Taiwan

Data source: National Health Research Institutes, Taiwan

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Taipei, Taiwan